Major Depression — A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder
Citation(s)
A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Adult Subjects With Moderate to Severe Major Depressive Disorder